Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Mar 29;113(3):542–551. doi: 10.1016/j.ijrobp.2022.03.007

Table 2.

Characteristics of Patient Population Enrolled on NSABP B-40 and B-41 by Receipt of RNI (N=1542)

Characteristic Received RNI (n=783) Did not receive RNI
(n=759)
P value
Age, median (range) years 49 (25-73) 49 (24-72) 0·529
Node-positive at entry, n (%) 484 (61·8%) 270 (35·6%) <0·001
Clinical tumor size, median (range) cm 5 (2-17·5) 4 (2-20) <0·001
Race, n (%) 0·745
     White 654 (84·3%) 630 (84·9%)
     Black 97 (12·5%) 93 (12·5%)
     Other 25 (3·2%) 19 (2·6%)
Ethnicity, n (%) 0·045
     Hispanic 73 (9·6%) 96 (13.1%)
     Non-Hispanic 684 (90·4%) 639 (86·9%)
HR-positive, n (%) 514 (65·6%) 427 (56·3%) <0·001
Mastectomy, n (%) 419 (53·5%) 338 (44·5%) 0·001
pCR breast, n (%) 254 (32·4%) 313 (41·2%) <0·001
pCR node, n (%) 356 (45·9%) 542 (73·7%) <0·001

Abbreviations: HR, hormone receptor; NSABP, National Surgical Adjuvant Breast and Bowel Project; pCR, pathological complete response